Lusvertikimab Biosimilar Monoclonal Antibody (IL-7R) for Research

Cat No.: GMP-Bios-ab-330

Pre-Made Lusvertikimab biosimilar, Whole mAb, Anti-IL7R Antibody: Anti-CD127/CDW127 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-330-1mg 1mg 3090

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Lusvertikimab biosimilar, Whole mAb, Anti-IL7R Antibody: Anti-CD127/CDW127 therapeutic antibody
INN Name Lusvertikimab
TargetIL7R
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesOSE Immunotherapeutics
Conditions Approvedna
Conditions ActiveAutoimmune diseases
Conditions Discontinuedna
Development Techna



About target - IL7R

1. Protein Interleukin-7 receptor subunit alpha

2. Gene IL7R

3. Organism Homo sapiens (Human)

Function
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).